Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases

Ori Elkayam; Jacob Ablin; Dan Caspi

doi:10.1016/j.autrev.2006.09.005

Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases

Ori Elkayam^*, Jacob Ablin, Dan Caspi

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

Abstract

Vaccination against streptococcus pneumonia is currently recommended for patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Safety and efficacy issues of vaccination in patients suffering from rheumatic diseases are still unresolved. This review summarizes the studies performed on the safety and immunogenicity of pneumococcal vaccination in patients with RA and SLE, with special emphasis on the effect of immunosuppressive drugs on the efficacy of the vaccine. Several trials have shown that the vaccine does not induce clinical exacerbation of RA and that it does induce an adequate humoral response, albeit one lower than that in healthy controls.

Original language	English
Pages (from-to)	312-314
Number of pages	3
Journal	Autoimmunity Reviews
Volume	6
Issue number	5
DOIs	https://doi.org/10.1016/j.autrev.2006.09.005
State	Published - Apr 2007
Externally published	Yes

Keywords

Pneumovax
RA
SLE
Vaccination

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.autrev.2006.09.005

Cite this

@article{322de779d84347b0863fe81467ef625d,

title = "Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases",

abstract = "Vaccination against streptococcus pneumonia is currently recommended for patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Safety and efficacy issues of vaccination in patients suffering from rheumatic diseases are still unresolved. This review summarizes the studies performed on the safety and immunogenicity of pneumococcal vaccination in patients with RA and SLE, with special emphasis on the effect of immunosuppressive drugs on the efficacy of the vaccine. Several trials have shown that the vaccine does not induce clinical exacerbation of RA and that it does induce an adequate humoral response, albeit one lower than that in healthy controls.",

keywords = "Pneumovax, RA, SLE, Vaccination",

author = "Ori Elkayam and Jacob Ablin and Dan Caspi",

year = "2007",

month = apr,

doi = "10.1016/j.autrev.2006.09.005",

language = "אנגלית",

volume = "6",

pages = "312--314",

journal = "Autoimmunity Reviews",

issn = "1568-9972",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases

AU - Elkayam, Ori

AU - Ablin, Jacob

AU - Caspi, Dan

PY - 2007/4

Y1 - 2007/4

N2 - Vaccination against streptococcus pneumonia is currently recommended for patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Safety and efficacy issues of vaccination in patients suffering from rheumatic diseases are still unresolved. This review summarizes the studies performed on the safety and immunogenicity of pneumococcal vaccination in patients with RA and SLE, with special emphasis on the effect of immunosuppressive drugs on the efficacy of the vaccine. Several trials have shown that the vaccine does not induce clinical exacerbation of RA and that it does induce an adequate humoral response, albeit one lower than that in healthy controls.

AB - Vaccination against streptococcus pneumonia is currently recommended for patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Safety and efficacy issues of vaccination in patients suffering from rheumatic diseases are still unresolved. This review summarizes the studies performed on the safety and immunogenicity of pneumococcal vaccination in patients with RA and SLE, with special emphasis on the effect of immunosuppressive drugs on the efficacy of the vaccine. Several trials have shown that the vaccine does not induce clinical exacerbation of RA and that it does induce an adequate humoral response, albeit one lower than that in healthy controls.

KW - Pneumovax

KW - RA

KW - SLE

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=33947717333&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2006.09.005

DO - 10.1016/j.autrev.2006.09.005

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 17412304

AN - SCOPUS:33947717333

SN - 1568-9972

VL - 6

SP - 312

EP - 314

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

IS - 5

ER -

Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this